Search

Search Constraints

You searched for: Author/Creator Ruszniewski, P

Search Results

2. 1316PImpact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. (23rd October 2018)

3. 1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (23rd October 2018)

4. 1328PUnmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals. (23rd October 2018)

5. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (13th August 2019)

10. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Issue 5 (1st November 2002)